Results 31 to 40 of about 55,609,055 (315)

Reproducibility of ambulatory blood pressure changes from the initial values on two different days

Clinics, 2013
OBJECTIVE: We tested the reproducibility of changes in the ambulatory blood pressure (BP) from the initial values, an indicator of BP reactivity and cardiovascular health outcomes, in young, healthy adults.
Garrett I. Ash, Timothy J. Walker, Kayla M. Olson, Jeffrey H. Stratton, Ana L. Gomez, William J. Kraemer, Jeff S. Volek, Linda S. Pescatello   +7 more
doaj   +1 more source

Paying clinicians to join clinical trials : a review of guidelines and interview study of trialists [PDF]

, 2009
Background: The motivations of clinicians to participate in clinical trials have been little studied. This project explored the potential role of payment for participation in publicly funded clinical trials in the UK.
Raftery James, Kerr Christine, Hawker, Sheila, Powell John, Powell, John, Hawker Sheila, Raftery, James, Kerr, Christine   +7 more
core   +1 more source

Clinical Trials in Portugal: Past and Future. Position Paper from the Colleges of Clinical Pharmacology and Pharmaceutical Medicine

Acta Médica Portuguesa
N/a.
Filipa Borges-Carneiro, Miguel Torre Souto, Isabel Silva, Paula Leão Moreira, Paula Ferraz de Oliveira, Diogo José Lopes, Luís Figueira, Marta Reina-Couto, Luís Cunha-Miranda, Diogo Ponces Bento, Fernando Magro   +10 more
doaj   +1 more source

Knowledge and Attitudes Towards Clinical Trial Participation in Oman: A cross-sectional study

Sultan Qaboos University Medical Journal, 2018
Objectives: Clinical trials are prospective studies on human subjects designed to answer various clinical questions. However, only a limited number of clinical trials have been conducted in Oman.
Hussain Al-Lawati, Khalid Al-Baimani, Mahra Al-Zadjali, Nasra Al-Obaidani, Ziyana Al-Kiyumi, Murtadha K. Al-Khabori   +5 more
doaj   +1 more source

Novel trial designs: Master protocol trials

Perspectives in Clinical Research
Conventional trial designs are resource and time-intensive. To accelerate the process of testing new interventions, we now have several novel research trial designs.
Priya Ranganathan, Vishal Deo, C. S. Pramesh, Mahesh P. Parmar   +3 more
doaj   +1 more source

Asking new questions with old data: The Centralized Open-Access Rehabilitation database for Stroke (SCOAR).

Frontiers in Neurology, 2016
Background: This paper introduces a tool for streamlining data integration in rehabilitation science, the Centralized Open-Access Rehabilitation database for Stroke (SCOAR), which allows researchers to quickly visualize relationships among variables ...
Keith Lohse, Sydney Y Schaefer, Sydney Y Schaefer, Adam Raikes, Lara Boyd, Catherine E Lang   +5 more
doaj   +1 more source

What can we learn from clinical trials of anticonvulsant drugs in epilepsy?

, 2002
Any physician who intends to utilize the available antiepileptic drugs (AEDs) judiciously, cannot do so without being well versed on their pharmacological properties and the large body of evidence that is continuously accumulating on their relative ...
What Can We Learn From Clinical Trials Of Anticonvulsant Drugs In Epilepsy?, PERUCCA, EMILIO   +1 more
core   +1 more source

Marketing and clinical trials : a case study [PDF]

, 2007
Background: Publicly funded clinical trials require a substantial commitment of time and money. To ensure that sufficient numbers of patients are recruited it is essential that they address important questions in a rigorous manner and are managed well ...
Francis, D, Francis, David, McDonald, Alison Mary, Knight, R.C, McDonald, A.M, Garcia Jo, McDonald Alison M, Francis, David; id_orcid, McDonald, Alison M, Vikki A Entwistle, Campbell, Marion K, Rosemary C Knight, Snowdon Claire, Entwistle, V.A, Campbell, Marion K., Francis David, Grant Adrian M, Knight, Rosemary C, Haleema Shakur, Entwistle Vikki A, Roberts, Ian, Entwistle, Vikki A., Elbourne, D.R, Shakur, H, Entwistle, Vikki, Mcdonald, Alison M., Campbell, Marion Kay, Snowdon, Claire, Grant, Adrian M, Garcia, J, David Francis, Diana R Elbourne, Alison M McDonald, Elbourne, Diana R., Roberts Ian, Shakur, Haleema, Elbourne, Diana R, Grant, Adrian Maxwell, Campbell Marion K, Entwistle, Vikki A, Snowdon, C, Campbell, M.K, Shakur Haleema, Grant, Adrian M., Knight, Rosemary C., Garcia, Jo, Adrian M Grant, Ian Roberts, Claire Snowdon, Grant, A.M, Marion K Campbell, Knight Rosemary C, Jo Garcia, Elbourne Diana R, Roberts, I   +54 more
core   +4 more sources

What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. [PDF]

, 2006
National Coordinating Centre for Research Methodology; Medical Research Council, UK Department of Health; Chief Scientist OfficeNot peer reviewedPublisher ...
McDonald, AM, Campbell, MK, Jonathan A Cook, Elbourne, DR, Cook, Jonathan Alistair, Francis, D, McDonald, Alison Mary, Francis, David, Knight, R.C, Knight, RC, Knight, Rosemary, McDonald, A.M, Grant, Adrian, Garcia Jo, McDonald, A, Cook, J, McDonald Alison M, Francis, David; id_orcid, McDonald, Alison M, Vikki A Entwistle, Campbell, Marion K, Rosemary C Knight, Snowdon Claire, Entwistle, V.A, Campbell, Marion K., Francis David, Entwistle, Vicky, Grant Adrian M, Knight, Rosemary C, Entwistle Vikki A, Cook, Jonathan A, Roberts, Ian, Cook, J.A, Grant, AM, Campbell, Marion, Cook, JA, Entwistle, Vikki A., Elbourne, D.R, Entwistle, Vikki, Campbell, Marion Kay, Snowdon, Claire, Grant, Adrian M, Garcia, J, David Francis, Elbourne, Diana, Diana R Elbourne, Alison M McDonald, Elbourne, Diana R., McDonald, Alison M., Roberts Ian, Elbourne, Diana R, Grant, Adrian Maxwell, Campbell Marion K, Entwistle, Vikki A, Snowdon, C, Campbell, M.K, Grant, Adrian M., Cook Jonathan A, Knight, Rosemary C., Garcia, Jo, Adrian M Grant, Ian Roberts, Entwistle, VA, Claire Snowdon, Grant, A.M, Marion K Campbell, Knight Rosemary C, Jo Garcia, Elbourne Diana R, Roberts, I, Cook, Jonathan A.   +70 more
core   +4 more sources

Assessment of outcome in clinical trials in mild Alzheimer 19s disease: urgent time for a rethink? [PDF]

, 2013
Introduction: A major barrier for clinical trials in Alzheimer's disease is the lack of sensitive clinical endpoints for the early stages. Until recently, regulatory agencies have required demonstration of improvement in two disease domains, cognition ...
McGoldrick, S., Duffy, Fiona, McGoldrick, Susan, Reynish, Emma, Kelly, Fiona, Morrison, Y., Wilson, L., Bennett, Crispin, Wilson, J T Lindsay, Bennett, C., Morrison, Yvonne, Duffy, F., Reynish, E.   +12 more
core